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Abstract:  Physiologically  Based  Pharmacokinetic  (PBPK)  models  can  be  used  to 
determine the internal dose and strengthen exposure assessment. Many PBPK models are 
available, but they are not easily accessible for field use. The Agency for Toxic Substances 
and Disease Registry (ATSDR) has conducted translational research to develop a human 
PBPK  model  toolkit  by  recoding  published  PBPK  models.  This  toolkit,  when  fully 
developed, will provide a platform that consists of a series of priority PBPK models of 
environmental pollutants. Presented here is work on recoded PBPK models for volatile 
organic compounds (VOCs) and metals. Good agreement was generally obtained between 
the original and the recoded models. This toolkit will be available for ATSDR scientists 
and  public  health  assessors  to  perform  simulations  of  exposures  from  contaminated 
environmental media at sites of concern and to help interpret biomonitoring data. It can be 
used as screening tools that can provide useful information for the protection of the public. 
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1. Introduction 
Default consumption values of air, water, soil, and foods are often used to estimate exposures to 
environmental pollutants from different routes of exposure. In addition, there is uncertainty regarding 
the amount of the chemical to which a person is exposed that is absorbed into the body and distributed 
to  organs  and  tissues.  Physiologically  based  pharmacokinetic  (PBPK)  models  are  being  used  to 
duplicate  biological  and  physiological  processes.  These  models  may  increase  the  accuracy  of 
calculating the internal dose in tissues by use of such measures as blood or urine levels [1–3]. For 
these reasons, PBPK models can be used for extrapolating varied routes, doses, and species [4–7]. 
Even though multiple PBPK models are available they are too complex for field application by 
health risk assessors. An additional challenge is they are in multiple simulation languages for which 
advance education and training is required. Thus, translational research is needed to make such models 
accurate  and  accessible  to  workers  in  easy-to-use  formats.  The  Agency  for  Toxic  Substances  and 
Disease Registry (ATSDR) has undertaken a project to convert and recode available, published PBPK 
models from multiple simulation languages into a single one that is easy to learn and operate. A library 
of models for certain ATSDR priority pollutants, such as volatile organic compounds (VOCs) and 
metals, has been developed, employing Berkeley Madonna software version
 8.01 for Windows, Kagi 
Shareware, Berkeley, CA, USA for simulation and optimization because of its ease of application, 
economical multi-user license, and faster compilation properties [8]. This toolkit will assist researchers 
and risk assessors to assess potential chemical health effects. These models are not intended to be 
state-of-the-art models with metabolites or the latest version of a PBPK model. They should, however, 
be sufficiently vetted to allow health assessors to predict the consequences of complex exposures in 
terms of internal doses and their health implications. The models, including a basic training module, 
will be freely available on the Computational Toxicology and Methods Development Laboratory Web 
page upon the project’s completion. Specifically, ATSDR staff will be provided initial training in the 
advantages and limitations of the models available in the human PBPK toolkit. This article focuses on 
the  project  achievements  to  date,  including  the  recoding  of  human  PBPK/PK  VOCs  and  metal  
models [9–11]. 
2. Methods 
We first conducted a review of the literature to identify available human PBPK models for the 
chemicals of interest. The PBPK models varied in their complexity. They contained different numbers 
of compartments (e.g., liver, kidney, and other organs) and metabolites, and they were developed by 
use of different simulation languages, such as MatLab™, Simusolve, and AcslX™. Model selection 
was based in part on the number of data sets used to calibrate and evaluate the model, the model’s 
maturity (number of predecessor models from which the model was derived), and the experience of the 
authors. The models’ availability, performance, accuracy, and reproducibility also played a role [12–23]. 
Each model was constructed by use of flow-limited compartments describing the mass balance of the 
chemicals in multiple tissues. All compartments were described as well-mixed and flow-limited. All 
the recoded models, unless otherwise specified, allow simulation of different routes of exposure, either 
individually or simultaneously.  Int. J. Mol. Sci. 2011, 12                      
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We derived a generic model that could be used for several VOCs, including benzene (BEN), carbon 
tetrachloride (CCl4), dichloromethane (DCM), perchloroethylene (PCE), trichloroethylene (TCE), and 
vinyl  chloride  (VC).  This  model  was  based  on  an  individual  model  that  met  the  study  criteria 
mentioned  above  [18–23].  Only  parent  compound  data  sets  and  accompanying  simulations  were 
extracted from figures by use of Grab It! XP2 [24]. Original model simulations for metabolites and 
metabolite data were not included in this version of the PBPK VOCs toolkit development. Including 
metabolites is a critical future improvement for use of the PBPK models in dose-response assessments, 
when toxicity is mediated by metabolite formation. 
For metals, arsenic, cadmium, and mercury models were recorded as original published. Because  
of chemical-specific kinetics differences in each model, no attempt was made to develop a generic  
model [12–17]. 
2.1. Model Structure and Physiological Parameters 
We constructed a seven-compartment  generic  VOCs model with blood, fat, skin, kidney, liver, 
rapidly and slowly perfused tissue compartments, plus a gas exchange compartment. Elimination and 
absorption were accounted for by incorporating a gas exchange and a skin compartment accounting for 
portal of entry and loss of the VOC from the body; the liver for metabolism, including first pass 
metabolism after oral intake; the fat as a reservoir; and the kidney as a possible target organ and 
potential excretory organ. Distribution to the remaining tissues was  grouped on the basis of rates  
of blood perfusion, to maintain mass balance. All compartments were described as well-mixed and  
flow-limited.  
Human physiological parameters used in this study such as tissue volumes, alveolar ventilation, rate 
of metabolism, cardiac output and chemical specific parameters were taken from the literature [18–36]. 
Only TCE [30] and PCE [36] skin:blood partition coefficients have been reported. Thus for the other 
VOCs, the TCE skin:blood partition coefficient values were used. To describe dermal uptake of other 
VOCs  dissolved  in  water,  we  would  need  estimates  of  skin:water  partition  coefficients  and  Kp 
(permeability  constant)  values.  The  dermal  exposure  route  is  available  in  the  model,  but  lack  of 
chemical-specific parameters and human pharmacokinetic data for this route of exposure is a major 
challenge  for  many  of  the  VOCs.  Several  approaches,  such  as  Quantitative  Structure  Activity 
Relationship (QSAR), have been used to fill this data gap and could be employed with these models to 
estimate the dermal contribution to exposure. In the current model version we also did not include 
original-model  simulations  for  metabolites  and  metabolite  data.  Nevertheless,  a  critical  future 
improvement  for  this  model’s  post-screening  use  is  incorporation  of  metabolite  information, 
particularly when toxicity is mediated by metabolite (s). 
The methylmercury model was patterned after Carrier et al., 2001. This model consists of blood, 
liver, kidney, brain, hair, urine, and feces compartments [13,14]. The arsenic model was patterned after 
El-Masri and Kenyon [12]; this model consists of interconnected sub-models for inorganic arsenic III 
and  V  and  its  metabolites,  monomethyl  arsenic  (MMA)  and  dimethylarsenic  (DMA).  It  includes 
compartments for the lung, liver, GI tract, kidney, muscle, brain, skin, and heart [24]. The cadmium 
model was based on the initial work of Nordberg-Kjellstrom, later modified by Choudhury et al., 2001 
and Diamond et al., 2003 [15,16]. Int. J. Mol. Sci. 2011, 12                      
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The cadmium toxicokinetics that used differential equations were to describe the inter-compartmental 
transfers  of  cadmium,  and  the  growth  algorithms  for  males  and  females  and  corresponding  organ 
weights were used to calculate age-specific cadmium concentrations from tissue cadmium burdens.  
Human physiological and chemical-specific parameters of As, Hg, and Cd were taken from the 
original  published  model  [12–17,27–31].  These  models  can  simulate  two  routes  of  exposure, 
inhalation and oral, either individually or simultaneously. 
2.2. Model Evaluation 
Assessment of our generic VOCs PBPK model was first performed by comparison of the published 
human kinetic data for each VOC and our recoded version of the published model. To further insure 
the reliability of our generic VOCs model, the area under the concentration curve (AUC) for blood or 
exhaled breath was calculated for each VOC, using both our generic VOCs model and the original 
model. Predicted AUC values in blood or breath for each VOC were then compared to the data-derived 
AUC values (using the trapezoidal rule) in blood or breath. For each VOC, the fit was expressed as a 
ratio (AUCr) that equaled the AUC value for the published model or for our generic VOCs model 
divided  by  the  AUC  value  computed  from  the  kinetic  data.  We  recognize  shortcomings  in  using  
data-derived  AUC  values,  in  that  they  may  either  inflate  or  deflate  the  probable  AUC  values, 
depending on the quality of the data. Nevertheless, our interpretation of the AUC ratios was that the 
closer the value was to one, the better the agreement between measured and model prediction. 
For  each  kinetic  time  course  dataset,  we  also  calculated  the  mean  of  the  sum  of  the  squared 
differences (MSSDs) between model prediction and observation. We computed MSSD by squaring the 
difference between a measured data point and the value of the simulation at the corresponding time. 
We summed these squares and then divided the sum by the number of data points. The MSSD was 
thus determined for both the published model and for our generic VOCs model. One interpretation is 
that the lower the MSSD value, the better the fit. However, the absolute values of the data can skew 
the results; thus, professional judgment is  considered important in  deciding the quality  of the  fits 
between model prediction and observation. 
Assessment  of  the  PBPK  metals  models  was  conducted  by  comparison  of  human  data  sets  to 
recoded  and published  model simulations. We achieved the  assessment by calculating a value  for 
percent median absolute performance error (MAPE%) on the basis of estimates of performance error 
(PE)  [14].  The  accuracy  of  the  prediction  was  measured  by  root  median-square  performance  
error (RMSPE%) as: 
2
1
PE
RMSPE%
n
i n =
= ∑  
where n is the total number of data points. We also calculated the correlation coefficient between 
Cmeasured and Cpredicted. 
The robustness of each of the recoded models was also studied by use of the sensitivity ratio (SR) 
approach.  This  type  of  sensitivity  analysis  shows  the  strength  and  relevance  of  the  inputs  in 
determining the variation in the output. The SR ratios for each input–output pair of variables were Int. J. Mol. Sci. 2011, 12                      
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calculated [37]. A positive sensitivity ratio indicates that an increase in the input value results in an 
increase in the output value. A negative sensitivity ratio indicates the opposite effect. 
3. Model Applications 
The  Centers  for  Disease  Control  and  Prevention’s  (CDC)  National  Health  and  Nutrition 
Examination Survey (NHANES) provides a representative sample of environmental testing on blood 
and urine specimens. With the NHANES data,  CDC’s Environmental Health  Laboratory conducts 
biomonitoring for over 200 chemicals [38]. All the VOCs as well as metals for which we have recoded 
models in our human PBPK toolkit have been  reported in the Fourth  National Report on Human 
Exposure to Environmental Chemicals [38]. 
We used our VOCs PBPK model to simulate various Minimal Risk Levels (MRLs) exposures for 
each of the VOCs for which biomonitoring data on human blood levels were available from the Fourth 
National Report on Human Exposure to Environmental Chemicals [38]. MRLs are an ATSDR estimate 
of daily human exposure to a hazardous substance at or below which that substance is unlikely to pose 
a measurable risk of harmful (adverse), noncancerous effects [39,40]. MRLs are calculated for an 
exposure route (inhalation or oral) over a specified period (acute, intermediate, or chronic). MRLs 
simulations were run as a combination of continuous 24 h inhalation and oral ingestion exposures 
(equally spaced four times a day) at the MRLs for acute (14 days), intermediate  (365 days), and 
chronic (>365 days) durations. Steady-state VOC concentrations in venous blood were then compared 
to NHANES data by use of these simplified assumptions about exposure frequency and duration. If the 
measured NHANES blood levels are below those estimated from the simulations, the exposures are 
regarded as safe. 
For the metals models, our toxicokinetic recoded model for cadmium was used to interpret the Cd 
urinary concentrations reported in the Fourth National Report on Human Exposure to Environmental 
Chemicals. Oral ingestion exposures were simulated by use of the geometric mean dietary Cd intakes 
for each of the sex-age stratified datasets [9]. 
4. Results and Discussion 
The seven-compartment generic VOCs model we constructed adequately reproduced simulations 
for all the VOCs. The simulations included various exposure scenarios for multiple routes and varying 
times of exposure for exhaled breath and arterial blood concentrations, as determined by the AUC 
ratios (AUCr) and the MSSD values (Table 1). A general acceptability within the modeling community 
is that the closer the value of the AUCr to one, the better the agreement between measured and model 
predictions. Similarly, the lower the MSSD value, the better the fit between the absorption, elimination, 
and steady state curves, as illustrated by the simulations shown for TCE (Figure 1). This figure shows 
the  original  model’s  and  our  generic  VOCs  model’s  comparative  simulations  of  predicted  arterial 
blood concentration following a 4-h, 50-ppm TCE inhalation exposure. These results show that our 
generic VOCs model simulation of TCE inhalation exposure in male humans compared favorably to 
the original model [22]. For both models, the AUCr values were 0.8 (Table 1); the MSSD values were 
similar and low—0.0089 for the original model and 0.0095 for our generic VOCs model. As seen in Int. J. Mol. Sci. 2011, 12                      
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Table  1,  sometimes  the  models  under-  or  over-predicted,  but  these  differences  are  within  the 
parameters of variability common for exposure assessment in risk assessments. 
Figure  1.  Trichloroethylene  (TCE)  blood  concentrations  (●)  measured  over  time, 
following a 4 h, 50 ppm TCE inhalation exposure (Fisher et al. 1998 [22]). The original 
simulation (---) and our generic VOCs model simulation (—) are also shown. 
 
Table  1.  Physiologically  Based  Pharmacokinetic  (PBPK)  volatile  organic  compounds 
(VOCs) Model Comparison. 
  AUCr  MSSD 
VOCs  Generic Model  Original Model  Generic Model  Original Model 
BEN 
a  0.9  1.6  0.0008  0.0009 
CCl4 
b  2.5  1.9  0.4515  0.2344 
DCM 
c  1.1  1.1  3.8214  1.1722 
PCE 
c  0.6  0.8  0.0805  0.0164 
TCE 
c  0.8  0.8  0.0095  0.0089 
VC 
b  1.2  1.1  0.1875  0.1831 
BEN,  benzene;  CCl4,  carbon  tetrachloride;  DCM,  dichloromethane;  PCE,  perchloroethylene;  
TCE, trichloroethylene; VC, vinyl chloride. 
a µM; 
b ppm; 
c mg/L.  
All the recoded metal models adequately simulated experimental human data found in the published 
literature [12–17]. As shown in Figure 2, the arsenic model predicted cumulative urinary excretion of 
total As and its two methylated metabolites in humans adequately, and the arsenic model is in good 
agreement with the original model. Performance evaluation was measured using MAPE%, MPE%, and 
RMSPE% for the three metals [10]. As is true with every PBPK and toxicokinetic model, these models 
try  to  capture  various  biological  processes  of  absorption,  distribution,  metabolism  and  excretion 
(ADME)  on  the  basis  of  available  experimental  data.  Such  simplifications  sometimes  can  lead  to 
shortcomings. Thus, model assumptions should be clearly understood and simulation interpretation 
should be put in perspective, with actual toxicity findings or reported facts. Int. J. Mol. Sci. 2011, 12                      
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After evaluation of each recoded model, we tried to interpret the findings of the report by using 
these models as a screening tool. The generic VOC PBPK model was used to estimate the blood 
concentrations  for  the  available  MRL  values  of  each  of  the  specific  VOCs  (Table  2),  and  the 
toxicokinetic Cd model was used to predict the urinary cadmium concentrations for non-smokers in the 
U.S. populations (Table 3). These results illustrate that the human PBPK toolkit can be used as an 
initial screening tool for some of the most prominent VOCs, and it can help direct further detailed 
analysis when such analysis is warranted. The application of the cadmium model demonstrated that it 
too can be used to predict urinary excretion on the basis of cadmium intake across various age groups, 
except for the elderly (>60 years of age), where absorption from the gut is a known compounding 
factor, as shown by other published models [15,16]. 
Figure 2. Total As, monomethyl arsenic (MMA), and dimethylarsenic (DMA) cumulative 
urinary excretion in human volunteers exposed to 100 µg As in the form of sodium arsenate 
(panel a) and sodium arsenite (panel b). Our recoded model simulation (Left, solid line) 
versus  the  reworked  original  simulation  by  El-Masri  and  Kenyon,  2008  [12]  (Right,  
solid line). 
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Table 2. Comparison of Minimal Risk Level (MRL) simulated blood concentration of each 
solvent, assuming simultaneous inhalation (24 h/day) and oral ingestion (4 drinking bouts 
per day) to the measured blood concentration of solvent reported by National Health and 
Nutrition Examination Survey (NHANES) 2003–2004. The simulated solvent exposure is 
set to the MRL for inhalation of the solvent in air and ingestion of the solvent in water. 
  BEN
+  CCl4
+  DCM
+  PCE
+  TCE
+  VC
+ 
MRL *   0.003/0.0005  0.03/0.007  0.6/0.2  0.3/0.06  0.2/0.05  2/0.2  none 
Exposure 
Duration 
Chronic  Intermediate  Acute  Chronic  Acute  Acute  ---- 
PBPK 
MODEL 
Blood Concentration (ng/mL) 
Predicted 
Peak 
0.04  0.40  18.12  6.70  10.76  111.65  ---- 
NHANES **  Blood Concentration (ng/mL) 
  0.260 
(0.210–0.320) 
<LOD  <LOD 
0.140 
(0.091–0.300) 
<LOD  ND ** 
Limit of 
Detection 
(LOD) 
0.024  0.005  0.07  0.048  0.012  ND 
Ben
+,  benzene;  CCl4
+,  carbon  tetrachloride;  DCM
+,  dichloromethane;  PCE
+,  perchloroethylene; 
TCE
+, trichloroethylene; VC
+, vinyl chloride; * Inhalation concentration (ppm)/Oral ingestion rate 
(mg/kg-day); ** NHANES 2003–2004. 95th percentiles of blood concentration (in ng/mL) for US 
population, ND = Not Done. 
Table  3.  Dietary  cadmium  intake,  model  predictions,  and  geometric  mean  urinary 
cadmium  concentrations  in  nonsmoking  male  U.S.  population  (National  Health  and 
Nutrition Examination Survey: NHANES 2003–2004). 
Age  
group 
(years) 
Males   Females 
* Urinary Cd (µg/g creatinine)  Cd Intake GM 
(µg/day) 
* Urinary Cd (µg/g creatinine)  Cd Intake GM 
(µg/day)  Measured  Predicted  Measured  Predicted 
6–11  0.088 
(0.071−0.11) 
0.101 
(0.071−0.11) 
15.0 
0.088 
(0.072−0.108) 
0.172 
(0.152−0.188) 
13.5 
12–19  0.074 
(0.066−0.083) 
0.087 
(0.078−0.095) 
19.7 
0.103 
(0.089−0.118) 
0.163 
(0.136−0.190) 
15.1 
20–39  0.125 
(0.114−0.137) 
0.137 
(0.082−0.190) 
22.4 
0.179 
(0.159−0.202) 
0.285 
(0.182−0.386) 
16.2 
40–59  0.208 
(0.184−0.234) 
0.214 
(0.188−0.241) 
22.1 
0.342 
(0.305−0.383) 
0.427 
(0.377−0.477) 
16.5 
≥60  0.366 
(0.324−0.414) 
0.226 
(0.221−0.232) 
17.6 
0.507 
(0.460−0.558) 
0.453 
(0.447−0.459) 
14.4 
 
* From Choudhury et al., 2001 [15]. GM = geometric mean. 
In this paper, we have reviewed the progress that has been made at ATSDR to make available 
PBPK  models  by  bridging  the  gap  between  model  development  and  use.  We  did  this  through 
harmonizing efforts of recoding the best available published PBPK models from multiple simulation Int. J. Mol. Sci. 2011, 12                      
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languages into a single simple simulation language—Berkeley Madonna—that when completed will 
be packaged into a human PBPK toolkit. Currently, the recoded models include three high-ranking 
metals  and  some  commonly  encountered  VOCs  from  ATSDR’s  priority  list  of  environmental 
contaminants. We have demonstrated that the toolkit can be used in the assessment of biomonitoring 
results as a screening tool. The human PBPK toolkit that is being developed at ATSDR has the major 
advantage that it can be applied in the field by practitioners of risk and health assessments. 
The  use  and  acceptance  of  computational  tools  such  as  the  human  PBPK  toolkit  in  the  
decision-making process should be acquired through an interaction between the model developers and 
model users. These interactions will lead to an increased application of such tools in the field and an 
increased awareness of their advantages and limitations. Such interactions and awareness will promote 
the integration of the toolkit into the alternative tools available for decision-makers. Their optimal use 
can only be realized through information exchange and shared expertise. The only way to promote 
their use is to make such tools easy to use and apply. We have shown that models available in multiple, 
simulation languages can be recoded into one simulation language. Thus, the end-user has to learn 
only one simple language, rather than a multitude of computer languages, to derive the predictions 
needed for risk assessments. These types of efforts will allow validation and verification of results to 
give the user confidence of their integration in the overall risk assessment processes. 
In conclusion, computational toxicology is a growing field that will produce new and innovative 
tools that will become increasingly available for chemical risk assessment. High throughput screening 
and  in  vitro  testing  are  drastically  changing  the  testing  strategies  in  toxicology.  They  are  at  the 
threshold of creating the next generation of computational tools. Before the nextGen tools become 
available, it is imperative that the risk assessors start using PBPK modeling and similar computational 
tools that have been developed during the past few decades. To keep pace with the changing science, 
we should continue to develop libraries of predictive tools that will help in the hazard identification 
and risk assessment process; otherwise, there is a real concern that the tools that are being employed 
might  not  keep  pace  with  advances  in  science  or  recommendations  of  such  organizations  as  the 
National  Academies  of  Science  (NAS).  These  organizations  are  recommending  a  totally  new  
approach, such as pathway analysis, and systems approaches to evaluate the consequences of exposure 
to chemicals.  
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